Maridebart cafraglutide + Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active💉Featured in GLP-1 & Metabolic Watch

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Obesity

Conditions

Obesity, Obstructive Sleep Apnea

Trial Timeline

Dec 19, 2025 → Sep 13, 2028

NCT ID

NCT07225686

About Maridebart cafraglutide + Placebo

Maridebart cafraglutide + Placebo is a phase 3 stage product being developed by Amgen for Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07225686. Target conditions include Obesity, Obstructive Sleep Apnea.

What happened to similar drugs?

20 of 20 similar drugs in Obesity were approved

Approved (20) Terminated (5) Active (0)

✅exenatide + PlaceboEli LillyApproved

✅TirzepatideEli LillyApproved

✅Micafungin + MicafunginAstellas PharmaApproved

✅MicafunginAstellas PharmaApproved

✅Zonegran + PlaceboEisaiApproved

✅lorcaserin hydrochloride XR + PlaceboEisaiApproved

✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07441252	Phase 2	Recruiting	Mar 5, 2026	Dec 22, 2027	Overweight or Obesity and Elevated Liver Fat
NCT07225686	Phase 3	Recruiting	Dec 19, 2025	Sep 13, 2028	Obesity
NCT07226765	Phase 3	Recruiting	Nov 25, 2025	Sep 13, 2028	Obstructive Sleep Apnea
NCT07160257	Phase 1	Recruiting	Aug 5, 2025	Dec 13, 2026	Type 2 Diabetes Mellitus
NCT07037433	Phase 3	Recruiting	Jul 25, 2025	Sep 29, 2030	Atherosclerotic Cardiovascular Disease
NCT07037459	Phase 3	Recruiting	Jun 25, 2025	Sep 29, 2030	Heart Failure With Preserved Ejection Fraction
NCT06987695	Phase 3	Active	Jun 13, 2025	Jul 21, 2027	Obesity Disease
NCT06858878	Phase 3	Active	Mar 17, 2025	Apr 16, 2027	Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
NCT06858839	Phase 3	Active	Mar 12, 2025	Apr 16, 2027	Obesity
NCT06660173	Phase 2	Active	Nov 7, 2024	Nov 10, 2026	Type 2 Diabetes Mellitus (T2DM)
NCT05669599	Phase 2	Completed	Jan 18, 2023	Dec 16, 2025	Obesity
NCT04478708	Phase 1	Completed	Aug 7, 2020	Nov 18, 2022	Obesity

Competing Products

20 competing products in Obesity

See all competitors

Product	Company	Stage	Hype Score
MK0493	Merck	Phase 2	35
MK0557	Merck	Phase 3	40
AMG 786	Amgen	Phase 1	29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo	Eli Lilly	Phase 2	39
Tirzepatide	Eli Lilly	Phase 2	42
exenatide + Placebo	Eli Lilly	Approved	43
Brenipatide	Eli Lilly	Phase 1	36
Orforglipron + Placebo	Eli Lilly	Phase 3	47
TERN-601	Terns Pharmaceuticals	Phase 2	32
MBX 4291 + Placebo	MBX Biosciences	Phase 1	30
PG-102	Rani Therapeutics	Phase 1	26
Orforglipron + Placebo	Eli Lilly	Phase 1	29
Tirzepatide + Placebo	Eli Lilly	Phase 3	40
Eloralintide + Placebo	Eli Lilly	Phase 1	29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo	Eli Lilly	Phase 2	27
LY3437943 + Midazolam + Warfarin + Caffeine	Eli Lilly	Phase 1	29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection	Skye Bioscience	Phase 2	29
Tirzepatide	Eli Lilly	Approved	50
Adenosine + Regadenoson	Astellas Pharma	Pre-clinical	26
Micafungin + Micafungin	Astellas Pharma	Approved	43